# Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

> **NCT00660816** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 46 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** pemetrexed disodium
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00660816
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2013-04
- **Final completion:** 2015-07
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2015-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00660816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00660816, "Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00660816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*